Botox onabotulinumtoxinA regulatory update

Allergan said that FDA extended by three months the PDUFA date for an sBLA for Botox onabotulinumtoxinA to treat chronic migraine. Allergan had submitted a modified REMS for the vacuum-dried purified ...